Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm
Minas P. Economides(NYU Langone Health), Naveen Pemmaraju(The University of Texas MD Anderson Cancer Center), Andrew A. Lane(Dana-Farber Cancer Institute), Deborah McCue(The University of Texas MD Anderson Cancer Center)
Cited by 21
Related Papers
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
|Cancer Discovery|2018|570
Ibrutinib and Venetoclax for First-Line Treatment of CLL
|New England Journal of Medicine|2019|502
Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias
|Nature Genetics|2016|486